[NH2:1][C:2]1[N:3]=[C:4]([CH:7]2[CH2:12][CH2:11][N:10]([C:13](=[O:25])[CH2:14][N:15]3[C:19]([CH3:20])=[CH:18][C:17]([C:21]([F:24])([F:23])[F:22])=[N:16]3)[CH2:9][CH2:8]2)[S:5][CH:6]=1.[C:26]1([N:32]=[C:33]=[O:34])[CH:31]=[CH:30][CH:29]=[CH:28][CH:27]=1.CO>C1COCC1>[CH3:20][C:19]1[N:15]([CH2:14][C:13]([N:10]2[CH2:11][CH2:12][CH:7]([C:4]3[S:5][CH:6]=[C:2]([NH:1][C:33]([NH:32][C:26]4[CH:31]=[CH:30][CH:29]=[CH:28][CH:27]=4)=[O:34])[N:3]=3)[CH2:8][CH2:9]2)=[O:25])[N:16]=[C:17]([C:21]([F:24])([F:23])[F:22])[CH:18]=1To a solution of 1-[4-(4-amino-thiazol-2-yl)-piperidin-1-yl]-2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-ethanone (100 mg, 0.27 mmol) in THF (5 mL) is added dropwise a solution of phenylisocyanate (30 μL, 0.28 mmol) in THF (1 mL) at 0° C. After stirring overnight at RT, methanol (1 mL) is added to the reaction mixture. After stirring 15 min. at RT, the solvents are evaporated and the residue was triturated with diethylether (5 mL) to induce precipitation. The resulting solid is filtered and dried under vacuum to give 1-(2-{1-[2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetyl]-piperidin-4-yl}-thiazol-4-yl)-3-phenyl-urea as beige solid (Compound No. I.g.024, 105 mg, 79%). M.p.=192.6° C. 1H-NMR (400 MHz, CDCl3): δ=1H-NMR (MeOD): d=1.65 (m, 1H), 1.80 (m, 1H), 2.40 (m, 2H), 2.30 (s, 3H), 2.98 (m, 1H), 3.30 (m, 1H), 3.39 (m, 1H), 4.10 (m, 1H), 4.52 (m, 1H), 5.22 (2d, 2H, diastereotopic), 6.42 (s, 1H), 7.05 (t, 1H), 7.09 (s, 1H), 7.26-7.45 (m, 6H). MS: m/z=494 (M+1).